646

Lipopolysaccharides, from E. coli O55:B5

646 Publications Verification

Synonyms: LPS, from Escherichia coli (O55:B5)

Category:

Natural Products Microorganisms Disease Research Fields Inflammation/Immunology

Target:

Lipopolysaccharides, from E. coli O55:B5 (LPS, from Escherichia coli (O55:B5)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O55:B5) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O55:B5 possess the typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O55:B5 activate TLR-4 in immune cells, exhibit high pyrogenicity, and demonstrate dose and serotype specificity. Lipopolysaccharides, from E. coli O55:B5 can be widely used to induce cellular inflammation and establish animal models related to inflammation .
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

116

Plerixafor

116 Cited Publications

Cat. No.: HY-10046

CAS No.: 110078-46-1

Purity: 99.90%

Synonyms: AMD 3100; JM3100; SID791

Target:

CXCR HIV

Research Areas:

Infection Inflammation/Immunology Endocrinology Cancer

Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC₅₀ of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC₅₀ of 1-10 nM .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

103

4-Octyl itaconate

103 Cited Publications

Cat. No.: HY-112675

CAS No.: 3133-16-2

Purity: 99.92%

Synonyms: 4-OI

Target:

Keap1-Nrf2

Research Areas:

Inflammation/Immunology

4-Octyl Itaconate is a cell-permeable Itaconate derivative. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1 .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

75

Fluo-4 AM

75 Cited Publications

Cat. No.: HY-101896

CAS No.: 273221-67-3

Fluo-4 AM is a cell-permeable Ca ²⁺ (calcium ion) indicator (Ex/Em = 485/526 nm) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

72

Exendin-4

72 Cited Publications

Cat. No.: HY-13443

CAS No.: 141758-74-9

Purity: 99.95%

Synonyms: Exenatide

Target:

GLP Receptor Apoptosis

Research Areas:

Cardiovascular Disease Metabolic Disease

Exendin‑4 (Exenatide) is an orally active, blood-brain barrier-permeable glucagon-like peptide-1 receptor (GLP‑1 receptor) agonist that resists degradation mediated by dipeptidyl peptidase IV. Exendin‑4 mediates multiple glucose-regulating effects, including stimulation of glucose-dependent insulin secretion, inhibition of glucagon production, increase in β-cell mass, delay of gastric emptying, reduction of food intake, improvement of peripheral insulin sensitivity, and restoration of normal islet structure. Exendin‑4 inhibits oxidative stress, alleviates inflammatory responses, and reduces neuronal apoptosis. Exendin‑4 reduces the aggregation level of mutant huntingtin, improves motor function, prolongs survival time, and regulates the expression levels of leptin and ghrelin. Exendin‑4 can be used in research related to type 2 diabetes, acute ischemic stroke, and Huntington's disease .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

72

Exendin-4 acetate

72 Cited Publications

Cat. No.: HY-13443A

CAS No.: 914454-01-6

Purity: 99.91%

Synonyms: Exenatide acetate

Target:

GLP Receptor Apoptosis

Research Areas:

Cardiovascular Disease Metabolic Disease

Exendin-4 acetate (Exenatide acetate) is an orally active, blood-brain barrier-permeable glucagon-like peptide-1 receptor (GLP‑1 receptor) agonist that resists degradation mediated by dipeptidyl peptidase IV. Exendin-4 acetate mediates multiple glucose-regulating effects, including stimulation of glucose-dependent insulin secretion, inhibition of glucagon production, increase in β-cell mass, delay of gastric emptying, reduction of food intake, improvement of peripheral insulin sensitivity, and restoration of normal islet structure. Exendin-4 acetate inhibits oxidative stress, alleviates inflammatory responses, and reduces neuronal apoptosis. Exendin-4 acetate reduces the aggregation level of mutant huntingtin, improves motor function, prolongs survival time, and regulates the expression levels of leptin and ghrelin. Exendin-4 acetate can be used in research related to type 2 diabetes, acute ischemic stroke, and Huntington's disease .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

47

Canagliflozin

47 Cited Publications

Cat. No.: HY-10451

CAS No.: 842133-18-0

Purity: 99.70%

Synonyms: JNJ 28431754

Target:

SGLT

Research Areas:

Metabolic Disease Cancer

Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

47

Canagliflozin hemihydrate

47 Cited Publications

Cat. No.: HY-I0383

CAS No.: 928672-86-0

Synonyms: JNJ 28431754 hemihydrate

Target:

SGLT

Research Areas:

Metabolic Disease Cancer

Canagliflozin hemihydrate (JNJ28431754 hemihydrate) is a selective SGLT2 inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

38

Epirubicin

38 Cited Publications

Cat. No.: HY-13624

CAS No.: 56420-45-2

Synonyms: 4'-Epidoxorubicin

Target:

DNA/RNA Synthesis Topoisomerase Apoptosis Antibiotic FOXP

Research Areas:

Cancer

Epirubicin (4'-Epidoxorubicin), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin inhibits DNA and RNA synthesis. Epirubicin is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

38

Epirubicin hydrochloride

38 Cited Publications

Cat. No.: HY-13624A

CAS No.: 56390-09-1

Purity: 99.15%

Synonyms: 4'-Epidoxorubicin hydrochloride

Target:

DNA/RNA Synthesis Topoisomerase Apoptosis Antibiotic FOXP

Research Areas:

Infection Neurological Disease Inflammation/Immunology Cancer

Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

35

Sitagliptin

35 Cited Publications

Cat. No.: HY-13749

CAS No.: 486460-32-6

Purity: 99.75%

Synonyms: MK-0431

Target:

Dipeptidyl Peptidase GLP Receptor PKA ERK

Research Areas:

Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Sitagliptin (MK-0431) is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

35

Sitagliptin phosphate

35 Cited Publications

Cat. No.: HY-13749A

CAS No.: 654671-78-0

Purity: 99.79%

Synonyms: MK-0431 phosphate

Target:

PKA ERK GLP Receptor Dipeptidyl Peptidase

Research Areas:

Infection Metabolic Disease Inflammation/Immunology Cancer

Sitagliptin (MK-0431) phosphate is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

35

Sitagliptin phosphate monohydrate

35 Cited Publications

Cat. No.: HY-13749B

CAS No.: 654671-77-9

Purity: 99.83%

Synonyms: MK-0431 phosphate monohydrate

Target:

GLP Receptor Dipeptidyl Peptidase PKA ERK

Research Areas:

Infection Metabolic Disease Inflammation/Immunology Cancer

Sitagliptin (MK-0431) phosphate monohydrate is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin phosphate monohydrate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate monohydrate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate monohydrate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate monohydrate can be used for the study of 1-type and 2-type diabetes .

Compare

loading...